Recent progress in dengue vaccine development (Q38303232)

1 September 2017

1 reference

title

Recent progress in dengue vaccine development (English)

1 reference

1 September 2017

0 references

3

Jing An

1 reference

1 September 2017

Jianchun Wei

1

1 reference

1 September 2017

Hui Chen

series ordinal

2

1 reference

1 September 2017

publication date

24 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

29

1 reference

1 September 2017

issue

6

1 reference

1 September 2017

page(s)

353-363

1 reference

T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

The global distribution and burden of dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

The 3'-nucleotides of flavivirus genomic RNA form a conserved secondary structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Is viral status needed before vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue: a continuing global threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Controversies in dengue pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Development of Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Surprising New Dengue Virus Throws a Spanner in Disease Control Efforts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Understanding the dengue viruses and progress towards their control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Electroporation delivery of DNA vaccines: prospects for success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Maternal antibody and viral factors in the pathogenesis of dengue virus in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Latest developments and future directions in dengue vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

The necessity and quandaries of dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Critical issues in dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

In pursuit of myosin function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

The human antibody response to dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Current progress in dengue vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-014-3542-7

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

21 January 2018

1 reference

12 December 2020

Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers

1 reference

12 December 2020

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

12 December 2020

Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys

1 reference

12 December 2020

Dengue vaccine candidates in development

1 reference

12 December 2020

Sanofi's dengue vaccine first to complete phase 3

1 reference

12 December 2020

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

1 reference

12 December 2020

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

1 reference

12 December 2020

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

1 reference

12 December 2020

ISCOMATRIX() vaccines: Safety in human clinical studies.

1 reference

12 December 2020

Genetically modified, live attenuated dengue virus type 3 vaccine candidates

1 reference

12 December 2020

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

1 reference

12 December 2020

AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types

1 reference

12 December 2020

Dengue viruses - an overview

1 reference

12 December 2020

Race is on for effective dengue vaccine

1 reference

12 December 2020

10.1007/S12250-014-3542-7

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1030551571

0 references

1 reference